AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06076525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidirectional Perturbations for Balance Control Assessment (60 perturbations)
Description: The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
Study NCT06076525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidirectional Perturbations for Balance Control Assessment (60 perturbations)
Description: The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
Study NCT06314607 — intervention group
Intervention type: GENETIC
Intervention: Prospective Biological Collection
Description: All samples that can be collected at each visit :~* Saliva sampling (added by the research)~* Collection of 2 to 4 additional tubes of blood (maximum 56mL) (added by the research if blood sampling in routine care)~* Urine and stool samples (added by the research)~* CSF sample residues (added by the research if lumbar punction in routine care)~* Lesion sample residues and surgical waste fragments (added by the research if surgery in routine care)
Study NCT06314607 — intervention group
Intervention type: GENETIC
Intervention: Retrospective Biological Collection
Description: Requalification of all biological samples obtained as part of ONCONEUROTEK research, with patient consent (blood, saliva, urine, Stool, CSF, lesion sample and surgical waste fragments)
Study NCT06020781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and dexmedetomidine.
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% + 1 μg/kg dexmedetomidine.
Study NCT06076525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidirectional Perturbations for Balance Control Assessment (150 perturbations)
Description: The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
Study NCT04632576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
Study NCT03987789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving-pressure-guided group
Description: Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers.
Study NCT03987789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low PEEP
Description: Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
Study NCT06392529 — intervention group
Intervention type: DRUG
Intervention: Voriconazole Powder
Description: The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
Study NCT04887857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Specified dose on specified days
Study NCT04887857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Specified dose on specified days
Study NCT05434559 — intervention group
Intervention type: DRUG
Intervention: Insulin Degludec
Description: Switch during standard routine care to Insulin Degludec.
Study NCT06020781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine only
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 20 ml bupivacaine 0.5% without additives
Study NCT06551207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w
Study NCT06020781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: patient will receive Ultrasound -guided Supraclavicular brachial plexus block with 30 ml bupivacaine 0.5% without additives as a control group.
Study NCT05989880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeLM as a supraglottic airway device with video capability
Description: The device will be inserted using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
Study NCT05989880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeLM as a supraglottic airway device without video capability
Description: The device will be blindly inserted without using the video capability and used as a primary airway device for the duration of the surgical procedure. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The position of the device will be confirmed by observing the video image of the glottis on the monitor. The adequacy of ventilation and oxygenation will be assessed by monitoring the patient's end-tidal CO2, pulse oximetry, and clinical signs of effective ventilation. Leak and cuff pressure will be assessed. The video capability of the device will be used to assess the accuracy of placement after the fact. The device will be removed at the end of the surgical procedure or if there are any signs of device malfunction, airway obstruction, or inadequate ventilation.
Study NCT05989880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeLM as a conduit for intubation using an endotracheal tube with video capability
Description: The device will be inserted, and an endotracheal tube will be advanced through the device under direct visualization using the video capability of the device. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening. The endotracheal tube will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device. The endotracheal tube will be advanced into the trachea, and the position will be confirmed by end-tidal carbon dioxide (EtCO2) detection and chest auscultation. The cuff of the endotracheal tube will be inflated, and mechanical ventilation will be resumed. The SafeLM device will be removed, and the position of the endotracheal tube will be confirmed once again.
Study NCT05989880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeLM as a conduit for intubation using a bougie with video capability
Description: The device will be inserted. Once the device is in place, the cuff will be inflated with the recommended volume of air to ensure an adequate seal around the laryngeal opening.The position of the device will be confirmed by observing the video image of the glottis on the monitor. The video camera on the SafeLM will be turned on to visualize the vocal cords.A standard airway bougie will be introduced through the working channel of the SafeLM under direct visualization using the video capability of the device.The SafeLM device will be removed, and an appropriately sized endotracheal tube will be advanced into the trachea. If a bougie is not able to be inserted into the tracheal under direct visualization, direct insertion of an endotracheal tube into the trachea will be attempted, followed by flexible scope intubation.
Study NCT06280599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional care model
Description: In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
Study NCT05817292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Probiotics
Description: Assumption of commercial probiotics
Study NCT05817292 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No assumption of probiotics
Study NCT06551207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fruquintinib
Description: Fruquintinib:5mg ,qd,po, d1-d14, q3w
Study NCT06551207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab:10mg/kg, ivgtt, d1, q3w
Study NCT06551207 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT:8-10Gy×5F, god, in 10 days
Study NCT06203613 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12
Description: The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.
Study NCT05568212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum doublet chemotherapy
Description: Investigator's choice platinum doublet chemotherapy
Study NCT04780425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESMOND
Description: as previously described
Study NCT04780425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual care as per standard treatment guidelines of Ghana unstructured/adhoc diabetes education during clinic visits
Study NCT05728658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-248
Description: Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
Study NCT05863039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: Strength training of the lower leg muscles using blood flow restriction
Study NCT05863039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular training type 1
Description: Strength training of the lower leg muscles using high loads
Study NCT05863039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular training type 2
Description: Strength training of the lower leg muscles using low loads
Study NCT06414213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI)
Description: Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.
Study NCT06414213 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Imagery (MI)
Description: Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.
Study NCT06414213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The participants received a 20-minute active session of tDCS at a 2-milliamp current.
Study NCT05799768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet counseling
Study NCT05330767 — intervention group
Intervention type: DEVICE
Intervention: DermaClose Continuous External Tissue Expander Device
Description: Constant tension and self-tensioning device. Supplied sterile and for single use only.
Study NCT05330767 — intervention group
Intervention type: DEVICE
Intervention: DermaClose XL Continuous External Tissue Expander Device
Description: Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
Study NCT06414213 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The participants received a 20-minute session of sham tDCS.
Study NCT04886011 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: just methyl cellulose gel was applied to the ulcer
Study NCT04886011 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: camel whey protein gel
Description: camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer
Study NCT05330767 — intervention group
Intervention type: DEVICE
Intervention: Conventional wound dressings
Description: Wet-to-dry, gauze, and negative pressure wound therapy.
Study NCT04720365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: play-based rehabilitaion
Description: usual re-education treatment by their physiotherapist
Study NCT04484272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).
Description: Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. \[three video banks of RDE + Support\]).
Study NCT04484272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Description: Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Study NCT05244629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMS vs. CS
Description: Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)
Study NCT05822791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prolonged cardiac monitoring
Description: Prolonged cardiac monitoring
Study NCT05822791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram
Study NCT05185102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
Study NCT05177029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 will be administered per schedule specified in the arm.
Study NCT05177029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
Study NCT05040295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 30 mg intact adult capsule
Study NCT05040295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 10 mg pediatric capsule
Study NCT05040295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritlecitinib
Description: 30 mg spray congealed beads
Study NCT06235060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted simulation technique training group
Description: After the training given with the demonstration method, the training videos on https://www.montgomerycollege.edu/academics/departments/nursing-tpss/nursing-simulation-scenario-library.html were shown to the participants using interactive training methods in parallel with this training.
Study NCT06235060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery GROUP
Description: After the training given with the demonstration method, scenarios suitable for the imagery technique were prepared by the second trainer (Ö.S.A.) in parallel with this training and CAST training.
Study NCT04804306 — intervention group
Intervention type: DEVICE
Intervention: Diagnostic Test: CBC-DIFF Monocyte Volume Width Distribution (MDW)
Description: MDW measurement used to detect sepsis. Results will not be used to manage patients.
Study NCT05180123 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament reconstruction
Description: Adolescent patients with confirmed full thickness ACL injury were operated arthroscopically with semitendinosus and gracilis autograft anatomical reconstruction.
Study NCT06564779 — intervention group
Intervention type: OTHER
Intervention: New memory assessment
Description: The intervention is part of the neuropsychological assessment carried out as part of routine care. It consists of carrying out the neuropsychological tests traditionally used to investigate the diagnostic hypothesis of Alzheimer's disease.
Study NCT05724849 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine
Description: See arm/group description.
Study NCT05724849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: See arm/group description.
Study NCT05724849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm/group description.
Study NCT06213402 — intervention group
Intervention type: OTHER
Intervention: Data collection from EHR.
Description: Collection of clinical and laboratory data. Reviwe of the electronic health record
Study NCT06045910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALETA-001
Description: ALETA-001 will be administered intravenously (IV) every two weeks.
Study NCT04647968 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary closure of tracheo-cutaneous fistula
Description: This procedure will follow protocoled steps. It consists of a sutured closure of the tracheotomy following local anesthesia, done at bedside.
Study NCT04647968 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Secondary closure of tracheo-cutaneous fistula
Description: This procedure will follow protocoled steps. It consists of removing the tracheotomy canula and applying ointment and an Elastoplast on the site, which will be changed regularly until full healing of the wound.
Study NCT05808712 — intervention group
Intervention type: OTHER
Intervention: validation
Description: Translation and validation design
Study NCT05923203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric and acoustic stimulation (EAS) technology in the implanted ear(s)-this is the combination of a cochlear implant (CI) and hearing aid (HA) in the implanted ear(s)
Description: This is a clinical fitting of an FDA approved EAS system for study participants that have received or who are scheduled to receive a CI based on clinical recommendations (i.e. not study related). The investigators will activate the CI sound processor's integrated HA circuit to allow for low-frequency acoustic amplification and mid-to-high frequency electric stimulation in the implanted ear(s) using recommended and accepted clinical practices and audiologic verification. EAS fitting will be completed using FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
Study NCT06210087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous pushing technique
Description: Pregnant women selected for the experimental group were trained on spontaneous pushing technique in the first stage of labor. During the second stage of labor, the women were encouraged and supported in this direction.
Study NCT06306456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH21
Description: Oral, 15mg BIW/6mg QD
Study NCT06306456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagrisso
Description: Oral, 80mg QD